OncoMatch/DIPG / Diffuse Midline Glioma/H3 K27M
DIPG / Diffuse Midline GliomaH3 K27M Clinical Trials
H3 K27M mutations in H3-3A (or H3C2/H3C3) define diffuse midline glioma — H3 K27-altered, a WHO grade 4 entity encompassing DIPG — and occur in >70% of pontine tumors in children and young adults. ONC201 (an agonist of the mitochondrial protease ClpP) received FDA approval for H3 K27M-mutant diffuse midline glioma in the recurrent/progressive setting. Trials investigate ONC201 combinations, radiation sensitizers, and novel H3 K27M-targeted immunotherapy approaches.
Top recruiting H3 K27M DIPG / Diffuse Midline Glioma trials
Ranked by phase and US site count. See all 4 trials matched to your profile →
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Shenzhen Geno-Immune Medical Institute
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Sabine Mueller, MD, PhD
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Emory University
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Baylor College of Medicine